Drug profile · INN
tiludronate disodium
SKELID
tiludronate disodium (SKELID) is a atp inhibitor. Route of administration: oral. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tiludronate disodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tiludronate disodium (SKELID) is a atp inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN tiludronate disodium
Brand SKELID
Mechanism ATP inhibitor
Target ATP
Route ORAL
Formulation TABLET
Mechanism of action
ATP inhibitor
Primary target: ATP
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tiludronate disodium?
tiludronate disodium (SKELID) is a atp inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tiludronate disodium?
SKELID is a marketed brand name for tiludronate disodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tiludronate disodium?
tiludronate disodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.